Introduction
It is well known that in patients with the acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), we use dual antiplatelet therapy (DAPT) for 12 months with the possibility of shortening it in case of an increased risk of bleeding complications. A similar consensus for patients with stable coronary artery disease (SCAD) is six months [1] . In patients with atrial fibrillation (AF), it is necessary to combine oral anticoagulant therapy (OAC) based on vitamin K antagonists (VKA) or new oral anticoagulants (NOAC), with DAPT as part of triple therapy (TT, triple therapy) [2] . TT (VKA + DAPT) provides better protection against thromboembolic complications compared to the single use of VKA, although the risk of bleeding complications increases by approximately 120%. In turn, double antithrombotic therapy (DT) consisting of VKA with a single antiplatelet therapy (SAT) provides worse protection from thromboembolic complications, although the increased risk of hemorrhagic complications is almost halved (about 60%) [3] . Antiplatelet and antithrombotic therapy constitutes even larger challenge in patients with cancer, however treatment of this group was described in other study by Banasiak et al. [4] .
The increasing use of radial artery access for angioplasty has significantly reduced the number of haemorrhagic complications. On the other hand, second generation drug-eluting stents (DES, everolimus, zotarolimus) allowed to radically shorten DAPT to three or even one month in patients with sinus rhythm and high risk of hemorrhagic complications [5] [6] [7] [8] . The introduction of stents with an ultrathin strut (60 μ) made it possible to further reduce the risk of stent thrombosis (ST) to 0.9% / year [9, 10] . It is worth mentioning that this value is lower than the percentage of bleeding complications during one year in patients treated with DAPT.
Moreover, it should be remembered that the improvement in stent implantation technique (high pressures, intravascular ultrasound (IVUS) control, optical coherence tomography (OCT)) leads to further reduction of ST risk. These achievements resulted in a more flexible approach to antithrombotic therapy in patients with AF and stent implantation. In practice, this means the possibility of shortening the time (as short as possible) and individualizing TT treatment. This fundamental change in treatment strategy is suggested by the results of trials comparing TT vs DT in patients with AF and stent implantation: WOEST [11] , ISAR-TRIPLE [12] , PIONEER AF-PCI [13] and RE-DUAL PCI [14] . In March 2019, the results of another trial-AUGUSTUS [15] -were published, which seems to have finally settled the problem.
The aim of the study is to present the results of a meta-analysis of randomized trials comparing TT vs DT in patients with AF and stent implantation.
Methods
Search strategy and selection criteria.
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines for the systematic review and meta-analysis.
The primary exclusion criteria were observational non-randomized studies, registry data, ongoing trials without results and duplicate studies. A search was conducted through PubMed, Embase, EBSCO, Cochrane database of systematic reviews, and Web of Science from its inception up to March 2019 using the following search terms in various combinations:
"percutaneous coronary intervention", "coronary stenting", "PCI", "triple antiplatelet therapy", "dual antiplatelet therapy", "triple therapy", "dual therapy", "double therapy", ,"vitamin K antagonists", "warfarin", "dabigatran", "apixaban", "rivaroxaban", "edoxaban", "aspirin", "thienopyridine", "clopidogrel", and "randomized clinical trial".
In addition, references of prior systematic reviews and meta-analysis, as well as abstracts from major cardiology meetings were screened for related studies. Two investigators (S.G., M.M.) independently reviewed the titles/abstracts and studies to determine their eligibility to meet the inclusion criteria. The same authors (S.G., M.M.) independently extracted all the relevant outcomes of interest into a structured data set.
In all studies included in the analysis, hemorrhagic complications were the primary endpoint. Due to the various definitions adopted in the studies, the following indicators of bleeding complications were included in the current meta-analysis: TIMI major + TIMI minor or International Society on Thrombosis and Haemostasis (ISTH Major or CNRM, clinically relevant non-major bleeding) or clinically significant bleeding. The definitions relevant to a particular study are summarized in Table S2 (Appendix). In each of the studies included in the analysis, the secondary endpoint defined as MACE (major adverse cardiac events) was also assessed slightly differently. Table S3 (Appendix) shows the relevant definitions for each study. Table S4 and S5 (Appendix) present the metadata used for the primary and secondary endpoints in each of the analyzed studies.
Statistical analysis
The meta-analyses were performed with the use of the DerSimonian and Laird method for random effects. Significant heterogeneity was identified in both analyses, as indicated by the I2 values. In general, I2 values of 25%, 50%, and 75% are considered to indicate low, moderate, and high degrees of heterogeneity, respectively. Relative weights are based on the inverse of the observed variance of the treatment effect within studies and between studies. In both therapeutic strategies, cardiovascular events (MACE) were almost identical -8.98% and 8.71%, in the DT arm vs in the TT arm, respectively, (odds ratio (OR) = 1.02; 95% CI, 0.86-1.21), (Figure 2a ). In the sensitivity analysis, after exclusion of the ISAR-TRIPLE study [12] (DT arm included acetylosalicylic acid in this study whereas in other studies clopidogrel was included), the respective values were: 9.29% in the DT arm vs. 
Discussion
The results of our meta-analysis clearly indicate that, with a similar reduction of MACE, the risk of bleeding complications in patients treated with DT is 43% lower than in the TT arm. The CHA₂DS₂VASC score values in the analyzed studies were similar in the AUGUSTUS [15] , RE-DUAL PCI [14] and PIONEER AF-PCI [13] and ranged from 3.3 to 4.1. Slightly lower -2.4 to 2.7 -were noted in WOEST [11] and ISAR-TRIPLE [12] trials. In studies which presented the HASBLED scale, the index values ranged from 2.7 to 3, so populations in terms of risk of cardiovascular events and bleeding complications did not differ drastically. New antiplatelet drugs (P₂Ὑ₁₂ inhibitor), ticagrelor in particular, were used extremely rarely, including 12% in the RE-DUAL PCI trial [14] , 4% in the PIONEER AF-PCI [13] trial and 5% in the AUGUSTUS [15] . In the WOEST [11] and ISAR-TRIPLE [12] studies, the new P₂Ὑ₁₂ inhibitors were not used. In both the DT and TT arms, over 90% of patients enrolled in the meta-analysis used clopidogrel. Slightly higher percentages of ticagrelor in the RE-DUAL PCI study does not allow to recommend new potent P₂Ὑ₁₂ inhibitors in chronic DT and TT treatment. This view is in line with current guidelines [1] .
Both in patients treated with VKA and NOAC, there were no significant differences in the frequency of MACE between the DT vs TT arms (Figures 2 and 3) , while in both subgroups (VKA and NOAC) we observed a lower risk of bleeding complications in DT vs TT arms, respectively 41% and 43%. (Figures 4 and 5) . Therefore, regardless of the base anticoagulant treatment (VKA or NOAC), the DT strategy compared with the TT arm significantly reduces the risk of bleeding complications, with unchanged effect on ischemic cardiovascular events.
Treatment with NOAC / VKA in combination with SAPT may raise some objections to the DAPT strategy commonly recommended after stent implantation, especially in patients with ACS. In the studies included in the meta-analysis, patients with ACS accounted for only 25% to 30% in both arms of the WOEST study [11] and similarly, from 30% to 33% in the ISAR -TRIPLE [12] study. In the PIONEER AF-PCI [13] and RE-DUAL [14] studies, patients with ACS accounted for half of the population in both arms (Table 1) , and all of them were treated with PCI. The highest number of patients with ACS was included in the AUGUSTUS study [15] (about 60-61%), but only 36% and 38% in both arms were treated with PCI, the remaining ones were treated conservatively. It is well known that in patients with ACS increased platelet activity is observed especially in the first 30 days after stent implantation, which results in an increased risk of early stent thrombosis (ST) with the highest mortality risk [16] .
While intuitively we are inclined to prefer DT in patients with SCAD starting from the first/second day after PCI, in ACS early DAPT cessation and the use of NOAC / VKA + SAPT may raise concerns. In the PIONEER AF-PCI [13] , RE-DUAL [14] and WOEST [11] trials, patients received DT 2-3 days after PCI (without aspirin, which was only given in the first 24-48 hours). In AUGUSTUS trial [15] , this period (median time from the index event to randomization) was 6 days. An important clinically observed fact is that in these studies TT was not even used for one month after the implantation of the stent. Only in ISAR-TRIPLE trial [12] , TT was administered for one month (6 weeks) in the experimental arm (DT arm) and then converted to DT until the end of the nine-month observation. However, in this study, about 2/3 of patients in both arms (TT and DT) were diagnosed with SCAD [12] . None of the mentioned studies included a separate assessment of DT and TT in patients with ACS and SCAD, which limits the conclusion. Doubts may be exacerbated by the fact that in the RE-DUAL study a marked, though statistically not significant, increase in the number of patients with myocardial infarction as well as stent thrombosis was noted with a 110 mg of dabigatran twice daily with clopidogrel when compared with TT [14] . The latest ESC guidelines on revascularization [1] recommend a 150 mg dose of dabigatran in patients treated with PCI. In the first PIONEER AF-PCI study [13] , due to the careful search for optimal TT strategy in patients with AF and stent implantation, the dose of rivaroxaban was lower (15mg) than recommended for patients with AF (20mg).
Differences in protocols of studies raise questions to which we have no definite answer.
Frequent changes in the European Society of Cardiology ESC and the European Heart
Rhythm Association (EHRA) guidelines express the uncertainty. In the Joint consensus published in 2018 [17] , it is recommended to implement DT directly after performing PCI 11,13,14,15] or TT for only one month and then chronically DT [12] in patients with AF after stent implantation and with an increased risk of bleeding complications. In patients with an increased risk of ischemic complications (ACS), the consensus proposes TT for 3 to 6 months and then DT up to the 12th month. Therefore, attention was paid to the possibility of shortening TT to 3 months. However, for patients with ACS and at the same time a high risk of bleeding complications, this period can be dangerously long. Recalling, in the PIONEER AF-PCI [13] and RE-DUAL [14] trials, ACS patients accounted for half of the subjects and DT (NOAC + SAPT) was used after PCI and the completion of intravenous anticoagulant therapy action. Improvement of stent implantation techniques, the III generation DES (ultrathin struts) [9, 10] significantly reduce the risk of stent thrombosis. In clinical practice, the choice of treatment in patients with AF and implanted stent in both SCAD and especially in ACS is much differed [18, 19] . Individualization of treatment seems to be the key to rational therapeutic decisions [20] .
It seems that in patients with AF and stent implantation, DT implemented immediately after PCI (24-48 hours) will replace TT in a subgroup of patients with SCAD. In patients with ACS with a too high risk of bleeding complications, TT will be used for one to three months and then converted to DT in the chronic treatment.
Hamlet's question remains -which of the antiplatelet drugs (SAPT) will be a component of DT? As previously mentioned, the experience from the RE-DUAL PCI trial [14] -in which 12% of patients used ticagrelor in combination with dabigatran -is insufficient to recommend a new, strong P₂Ὑ₁₂ in combination with NOAC / VKA in DT as well as in TT. Thus, acetylosalicylic acid or clopidogrel? In the WOEST study [11] , in patients treated with DT (clopidogrel + VKA) compared with TT (acetylosalicylic acid, clopidogrel and VKA), a greater reduction of the secondary composite ischemic endpoint (HR 0.60 (0.38-0.94)) was observed. Also, the primary endpoint (bleeding complications) was significantly less frequent in patients treated with DT vs TT, HR 0.36 (0.26-0.50). In the Scandinavian registry [21] , in patients with AF and myocardial infarction after the stent implantation, the greatest benefits (reduction of cardiovascular mortality, total mortality, myocardial infarction and stroke) with similar indices of bleeding complications were observed in patients treated with VKA + clopidogrel vs. VKA, clopidogrel and acetylosalicylic acid. In turn, in the ADAPT-DES study [22] in patients with sinus rhythm, after II generation DES implantation (zotarolimus) acetylosalicylic acid was added to clopidogrel (resistance to both drugs was evaluated), and after 12 months had no effect on the reduction of ischemic complications (stent thrombosis, myocardial infarction), whereas a significant induction of increase in bleeding complications was observed. At present, at the AHA Congress in New Orleans, the results of two randomized studies (STOPDAPT-2 and SMART CHOICE) comparing DAPT (acetylosalicylic acid + clopidogrel) vs SAPT (clopidogrel after 1 or 3 months of acetylosalicylic acid withdrawal) were presented. In the STOPT DAPT study, after 12 months of observation, the net clinical endpoint (ischemic + hemorrhagic complications) was significantly lower in the group treated with clopidogrel vs. DAPT; 2.4% vs. 3.7% respectively, p <0.04 [23] . In the SMART CHOICE study, there were no significant differences in MACE between the arm treated with clopidogrel monotherapy vs. DAPT -2.9% vs. 2.5%, ns. Hemorrhagic complications (BARC 2-5) were observed less frequently with clopidogrel therapy compared to DAPT -respectively 2.0% vs 3.4%, p <0.04 [24] . Recalling, in the CAPRIE study [25] , in patients at high risk of ischemic complications treated with clopidogrel compared to acetylosalicylic acid, a significant reduction in the composite endpoint (cardiovascular death, myocardial infarction, stroke) and significantly less frequent gastrointestinal bleeding complicationswere observed. Already in 2014, EHRA / ESC guidelines in patients with AF after stent implantation preferred the use of clopidogrel in DT [26] . When analyzing the results of our meta-analysis, it may be noticed that only in the ISAR-TRIPLE trial [12] in the DT group there was no significant reduction in haemorrhagic complications compared to TT (Figures 4a and 5a) . In this study, the experimental arm (DT) was based on the combination of VKA with acetylosalicylic acid vs. VKA + acetylosalicylic acid + clopidogrel.
Conclusions
In patients with AF and stent implantation, the results of our meta-analysis are clearly in line with the current trend of the fastest possible reduction in the use of TT in favor of DT. Due to the increased risk of bleeding complications (the need for anticoagulation), the duration of DT should be considered individually depending on the risk assessment of ischemic complications (ACS, GRACE score> 140, Syntax score) and bleeding complications. 
